Odylia Therapeutics is a non-profit corporation working to help develop gene therapies for rare eye disease. Recently, we talked to Harrison Brown, PhD, BBA, the company’s Chief Science Officer about advances in gene therapy.
As Dr. Brown explains in this video, the use of AAV vectors to develop gene therapies has been around for about 15 years. That means there patent protections are about the expire which will likely lead to an explosion of new, more affordable, gene therapies. In addition, Dr. Brown believes the next generation of gene therapies will allow for the rational engineering of these viruses that may not be available in nature.
“Gene therapy is finally coming of age. There are commercial products out there now and we have seen that these treatments can provide life altering, durable therapies for diseases that were previously undruggable,” noted Dr. Bown, adding, “As we gain more experience doing this, I think we will see a broader array of diseases be treated, and hopefully for diseases with incredibly rare population sizes.”
For more information, visit https://odylia.org/